Aetna modified CPB 0731, covering convection-enhanced intraparenchymal drug delivery and MR-guided focused ultrasound blood-brain barrier disruption, effective November 27, 2025. Here's what changes for billing teams.
Aetna, a CVS Health company, updated CPB 0731 in the Aetna brain drug delivery coverage policy to classify two techniques as experimental, investigational, or unproven: convection-enhanced delivery of drugs into brain parenchyma, and low-intensity MR-guided focused ultrasound (MRgFUS) mediated disruption of the blood-brain barrier. The update directly affects CPT 0947T — the Category III code for MRgFUS stereotactic blood-brain barrier disruption — which Aetna now explicitly lists as not covered for any indication in this policy. If your team bills for neuro-oncology, neurosurgery, or neurological disorder treatments under ICD-10 codes in the C71.x or G30.x families, this policy change applies to you.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Selected Techniques for Delivery of Drugs to the Brain |
| Policy Code | CPB 0731 |
| Change Type | Modified |
| Effective Date | November 27, 2025 |
| Impact Level | High |
| Specialties Affected | Neurosurgery, Neuro-oncology, Neurology, Radiation Oncology |
| Key Action | Flag CPT 0947T as non-covered in your charge master and deny prevention queues before submitting any claims with this code to Aetna |
Aetna Brain Drug Delivery Coverage Criteria and Medical Necessity Requirements 2025
The Aetna brain drug delivery coverage policy under CPB 0731 Aetna system establishes a clear position: there is no covered pathway for convection-enhanced intraparenchymal drug delivery or MRgFUS-mediated blood-brain barrier disruption under any indication.
These are not prior authorization denials. They're blanket experimental classifications. That distinction matters for your revenue cycle team because the appeal strategy for an experimental designation is fundamentally different from a failed medical necessity review.
When Aetna calls something experimental, they're saying the clinical evidence base doesn't yet support safety and effectiveness — not that the patient failed to meet a checklist. Prior authorization won't unlock reimbursement here. You can get a prior auth number and still get a claim denial on the back end because the service itself is excluded.
This is a complete non-coverage policy. There are no medical necessity criteria to meet because Aetna doesn't recognize a covered version of these procedures at all. If your physicians are performing these techniques and your patients have Aetna commercial coverage, the financial exposure falls on the provider unless you have a valid ABN equivalent or patient financial counseling in place before the procedure.
Aetna Convection-Enhanced Delivery and MRgFUS Exclusions and Non-Covered Indications
Aetna's CPB 0731 coverage policy designates two specific techniques as experimental, investigational, or unproven.
Convection-enhanced intraparenchymal drug delivery involves using a pressure gradient to infuse drugs directly into brain tissue, bypassing the blood-brain barrier. Aetna's position is that safety and effectiveness have not been established for this approach.
Low-intensity MR-guided focused ultrasound (MRgFUS) mediated disruption of the blood-brain barrier is a technique that uses focused ultrasound — often in combination with microbubbles — to temporarily open the blood-brain barrier and allow drugs to penetrate brain tissue. CPT 0947T is the billing code for this procedure. Aetna explicitly lists it in the non-covered group for all indications in this CPB.
The ICD-10 diagnosis codes attached to this policy span a wide range: primary brain tumors (C71.0–C71.9), secondary malignant neoplasms of the brain (C79.31, C79.49), Alzheimer's disease (G30.0–G30.9), and epilepsy and seizure disorders (G40.001–G40.909, R56.1, R56.9). None of these diagnoses create a covered pathway. Aetna lists them because these are the conditions clinicians are treating when they use these techniques — not because any of them trigger coverage.
This is worth flagging to your medical director and compliance officer. These are serious, high-acuity diagnoses. The temptation to submit anyway — especially for a patient with end-stage glioblastoma — is real. But the claim denial will come, and the write-off will follow.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Convection-enhanced intraparenchymal drug delivery — brain tumors | Not Covered / Experimental | C71.0–C71.9 | No covered pathway; experimental designation |
| Convection-enhanced intraparenchymal drug delivery — brain metastases | Not Covered / Experimental | C79.31, C79.49 | No covered pathway; experimental designation |
| MRgFUS blood-brain barrier disruption — brain tumors | Not Covered / Experimental | CPT 0947T, C71.0–C71.9 | Explicitly non-covered; prior auth will not override |
| MRgFUS blood-brain barrier disruption — Alzheimer's disease | Not Covered / Experimental | CPT 0947T, G30.0–G30.9 | Experimental designation; no reimbursement pathway |
| MRgFUS blood-brain barrier disruption — epilepsy and seizures | Not Covered / Experimental | CPT 0947T, G40.001–G40.909, R56.1, R56.9 | Experimental designation; no reimbursement pathway |
Aetna Brain Drug Delivery Billing Guidelines and Action Items 2025
These are direct steps your billing team should take now, given the November 27, 2025 effective date.
| # | Action Item |
|---|---|
| 1 | Flag CPT 0947T as non-covered in your charge master today. Don't wait for a claim denial to discover this. If 0947T is in your charge description master and your facility has Aetna commercial contracts, add a billing edit that routes this code to a financial counseling or prior authorization review queue before claims drop. The goal is to catch it before submission, not after. |
| 2 | Audit any CPT 0947T claims submitted to Aetna after November 27, 2025. Pull a 90-day look-back on 0947T claims. If any went to Aetna and got paid, watch for recoupment. If they're still in process, expect denial. Start the appeal clock now if you believe the procedure qualifies under a different benefit structure — but understand that appeals on experimental designations rarely succeed without new published clinical evidence. |
| 3 | Check your denial prevention queues for convection-enhanced delivery procedures. There's no single CPT code for convection-enhanced intraparenchymal delivery listed in this policy, but these procedures are typically billed under neurosurgery codes. Review your open claims for patients with C71.x or C79.31/C79.49 diagnoses who had intracranial drug infusion procedures. If those were billed to Aetna, they may be at risk. |
| 4 | Update your patient financial counseling workflows before performing either procedure on Aetna members. If your physicians plan to continue offering these techniques — which is clinically appropriate in many academic and investigational settings — your financial counselors need a script. Patients must understand before the procedure that Aetna will not cover it. Get signatures. Document the conversation. |
| 5 | Don't rely on prior authorization as coverage confirmation. Aetna's experimental designation means prior auth is irrelevant. If someone on your team calls Aetna and gets a prior auth number for CPT 0947T, that number does not guarantee payment. The claim will still deny on the back end. Train your prior auth team to recognize this distinction — authorization is not the same as coverage. |
| 6 | Loop in your compliance officer if you're operating in a research or clinical trial context. Some facilities perform these procedures under IRB-approved trials. Billing in that context involves a completely different set of rules — including what can and can't be billed to a commercial payer. If you're not sure where the line is, talk to your compliance officer before submitting anything. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Brain Drug Delivery Under CPB 0731
Not Covered / Experimental CPT Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| 0947T | CPT (Category III) | Magnetic resonance image guided low intensity focused ultrasound (MRgFUS), stereotactic blood-brain barrier disruption | Not covered for any indication listed in CPB 0731; Aetna considers this experimental, investigational, or unproven |
There are no covered CPT codes in CPB 0731. This policy contains only exclusions.
Key ICD-10-CM Diagnosis Codes Referenced in CPB 0731
These codes represent the diagnoses Aetna associates with the techniques addressed in this policy. None of these diagnoses create a covered pathway for the procedures in CPB 0731.
| Code | Description |
|---|---|
| C71.0 | Malignant neoplasm of brain |
| C71.1 | Malignant neoplasm of brain |
| C71.2 | Malignant neoplasm of brain |
| C71.3 | Malignant neoplasm of brain |
| C71.4 | Malignant neoplasm of brain |
| C71.5 | Malignant neoplasm of brain |
| C71.6 | Malignant neoplasm of brain |
| C71.7 | Malignant neoplasm of brain |
| C71.8 | Malignant neoplasm of brain |
| C71.9 | Malignant neoplasm of brain |
| C79.31 | Secondary malignant neoplasm of brain and other parts of nervous system |
| C79.49 | Secondary malignant neoplasm of brain and other parts of nervous system |
| G30.0 | Alzheimer's disease |
| G30.1 | Alzheimer's disease |
| G30.2 | Alzheimer's disease |
| G30.3 | Alzheimer's disease |
| G30.4 | Alzheimer's disease |
| G30.5 | Alzheimer's disease |
| G30.6 | Alzheimer's disease |
| G30.7 | Alzheimer's disease |
| G30.8 | Alzheimer's disease |
| G30.9 | Alzheimer's disease |
| G40.001–G40.909 | Epilepsy and recurrent seizures |
| R56.1 | Post-traumatic seizures |
| R56.9 | Unspecified convulsions |
A Note on the Broader Pattern Here
This update fits a consistent Aetna pattern for emerging neurotechnology. MRgFUS has coverage under some Aetna policies for other indications — essential tremor treatment, for example, is covered under a separate CPB. But Aetna draws a firm line between FDA-cleared, well-studied applications and emerging uses that are still in clinical trial phases.
The blood-brain barrier disruption application of MRgFUS is genuinely early-stage. Published data is promising but limited. Aetna's decision to classify it as experimental is defensible from a clinical evidence standpoint, even if it's frustrating for practices and patients who are out of other options.
That doesn't make the billing consequences any less real. CPT 0947T is a Category III code — already a signal that the technology is emerging. Category III codes sometimes get covered by payers before they're converted to Category I. Here, Aetna is moving in the opposite direction: explicitly calling out 0947T as non-covered. Watch for other payers to follow.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.